 Julie Goddard
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Free Tissue Flaps | 4 | 2023 | 52 | 1.010 |
Why?
| | Head and Neck Neoplasms | 7 | 2023 | 606 | 1.000 |
Why?
| | Otolaryngologists | 1 | 2018 | 13 | 0.590 |
Why?
| | Microsurgery | 1 | 2018 | 75 | 0.570 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 683 | 0.550 |
Why?
| | Parotitis | 1 | 2017 | 6 | 0.550 |
Why?
| | Parotid Gland | 1 | 2017 | 23 | 0.540 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 119 | 0.510 |
Why?
| | Vascular Malformations | 1 | 2017 | 52 | 0.510 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 307 | 0.440 |
Why?
| | Lymph Node Excision | 2 | 2019 | 171 | 0.410 |
Why?
| | Thyroidectomy | 1 | 2013 | 106 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 1079 | 0.380 |
Why?
| | Carcinoma | 1 | 2013 | 240 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1313 | 0.310 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 343 | 0.300 |
Why?
| | Eyelids | 1 | 2022 | 37 | 0.190 |
Why?
| | Orbit | 1 | 2022 | 70 | 0.180 |
Why?
| | Laryngectomy | 2 | 2018 | 19 | 0.180 |
Why?
| | Margins of Excision | 2 | 2018 | 50 | 0.180 |
Why?
| | Laryngeal Neoplasms | 2 | 2020 | 39 | 0.170 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.170 |
Why?
| | Mouth | 1 | 2020 | 87 | 0.170 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 352 | 0.170 |
Why?
| | Larynx | 1 | 2020 | 60 | 0.170 |
Why?
| | Survival Rate | 3 | 2019 | 1972 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 9 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 344 | 0.160 |
Why?
| | Reoperation | 2 | 2018 | 573 | 0.150 |
Why?
| | Lymph Nodes | 2 | 2019 | 491 | 0.150 |
Why?
| | Pharyngectomy | 1 | 2018 | 3 | 0.150 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 325 | 0.150 |
Why?
| | Medicare | 2 | 2020 | 773 | 0.140 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2018 | 63 | 0.140 |
Why?
| | Nomograms | 1 | 2018 | 54 | 0.140 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 120 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 10 | 0.130 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 16 | 0.130 |
Why?
| | Parotid Diseases | 1 | 2017 | 5 | 0.130 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 17 | 0.130 |
Why?
| | Surgical Flaps | 1 | 2018 | 130 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 273 | 0.130 |
Why?
| | Nose Neoplasms | 1 | 2017 | 25 | 0.130 |
Why?
| | Canada | 1 | 2018 | 418 | 0.130 |
Why?
| | Parotid Neoplasms | 1 | 2017 | 16 | 0.130 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 28 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 76 | 0.130 |
Why?
| | Microvessels | 1 | 2017 | 88 | 0.130 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 10 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 306 | 0.110 |
Why?
| | Humans | 20 | 2023 | 137585 | 0.110 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 213 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 740 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1060 | 0.110 |
Why?
| | Postoperative Complications | 3 | 2023 | 2654 | 0.100 |
Why?
| | Ultrasonography | 1 | 2017 | 759 | 0.100 |
Why?
| | Female | 11 | 2019 | 73304 | 0.100 |
Why?
| | Disease-Free Survival | 3 | 2020 | 686 | 0.100 |
Why?
| | Male | 12 | 2022 | 67762 | 0.090 |
Why?
| | Aged | 10 | 2020 | 23961 | 0.090 |
Why?
| | Middle Aged | 9 | 2020 | 33479 | 0.090 |
Why?
| | United States | 5 | 2020 | 14841 | 0.090 |
Why?
| | Adult | 8 | 2022 | 37929 | 0.080 |
Why?
| | Melanoma | 1 | 2017 | 760 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1389 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2023 | 15657 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3566 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1357 | 0.070 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 404 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 804 | 0.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1692 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5472 | 0.070 |
Why?
| | Anion Transport Proteins | 1 | 2006 | 9 | 0.070 |
Why?
| | Directed Molecular Evolution | 1 | 2006 | 21 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6828 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2017 | 220 | 0.060 |
Why?
| | Alphapapillomavirus | 2 | 2018 | 39 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 389 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 5778 | 0.060 |
Why?
| | Prognosis | 3 | 2019 | 4030 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1236 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1325 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1266 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1509 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2006 | 493 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 153 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 64 | 0.050 |
Why?
| | Injections | 1 | 2022 | 183 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 261 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 224 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 270 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2020 | 135 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 294 | 0.040 |
Why?
| | Hypopharynx | 1 | 2018 | 3 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 145 | 0.040 |
Why?
| | Anticoagulants | 1 | 2023 | 664 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 129 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 342 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 43 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 49 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 40 | 0.030 |
Why?
| | Critical Care | 1 | 2022 | 601 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 68 | 0.030 |
Why?
| | Office Visits | 1 | 2017 | 93 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7635 | 0.030 |
Why?
| | Vocal Cords | 1 | 2016 | 32 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 225 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 294 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2016 | 109 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 889 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 1096 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1289 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1316 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 898 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2020 | 654 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 10811 | 0.030 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 98 | 0.020 |
Why?
| | Length of Stay | 1 | 2018 | 1215 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 366 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1226 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 872 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1178 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2013 | 614 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5131 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1738 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 644 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3457 | 0.020 |
Why?
| | Renilla | 1 | 2006 | 3 | 0.020 |
Why?
| | Organic Anion Transporters | 1 | 2006 | 12 | 0.020 |
Why?
| | Gerbillinae | 1 | 2006 | 65 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2691 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5742 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2006 | 109 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 374 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 570 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2017 | 6079 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10388 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9465 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2139 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11074 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2900 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2847 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 13209 | 0.010 |
Why?
| | Animals | 2 | 2013 | 36940 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 21513 | 0.010 |
Why?
| | Child | 1 | 2017 | 21935 | 0.010 |
Why?
| | Mice | 1 | 2013 | 17787 | 0.010 |
Why?
|
|
Goddard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|